Showing papers by "Todd E. DeFor published in 2015"
TL;DR: A novel composite end point of GV HD-free/relapse-free survival (GRFS) in which events include grade 3-4 acute GVHD, systemic therapy-requiring chronic GVhd, relapse, or death in the first post-HCT year is examined.
364 citations
TL;DR: In this paper, the authors developed a novel acute graft-versus-host disease (GVHD) risk score using clinical grouping, descriptive statistics and recursive partitioning to identify poorly responsive, high-risk (HR) acute GVHD by the number of involved organs and severity.
166 citations
TL;DR: Alternative donor HCT is now associated with excellent survival for patients without prior opportunistic infections or transfusions and should be considered for all FA patients after the onset of marrow failure.
82 citations
TL;DR: It is hypothesized that patients with abundant AF involved in repair/regeneration versus those mediating damage/inflammation would have improved outcomes and, thus, may contribute to both pathogenesis and recovery.
51 citations
TL;DR: It is suggested that persistent/nonreplicating recipient CMV induces rapid production of adaptive NK and T cells from mature cells from sibling but not UCB grafts, associated with protection from CMV reactivation.
49 citations
TL;DR: Clinical outcomes of reduced-intensity conditioning (RIC) double umbilical cord blood HCT recipients receiving cyclosporine A with MMF 2 g versus 3 g daily are compared to indicate that MMF 3 g/day reduces the risk of acute GVHD without affecting other clinical outcomes and should be used for GV HD prophylaxis after RIC dUCB transplantation.
37 citations
TL;DR: MK cytogenetics in MDS are associated with poor survival, suggesting the need for alternative or intensified approaches to their treatment, and IPSS and R-IPSS discriminated good/very good groups from poor/very poor groups, patients with intermediate-risk scores had the worst outcomes and, therefore, these scores did not show a progressive linear discriminating trend.
17 citations
TL;DR: Mthap may be an important consideration in HCT outcomes, although validation and functional studies are needed and it may be feasible to select donors based on mthap to increase positive or decrease negative outcomes.
8 citations
TL;DR: ACEI, enalapril, does not appear to alter the PK of DOX, and ongoing efforts to determine the effectiveness of ACEI as a cardioprotective agent in women receiving DOX chemotherapy should be continued.
Abstract: Doxorubicin (DOX) chemotherapy can cause cardiac complications. Angiotensin converting enzyme inhibitors (ACEI) may protect against these complications. We performed a pharmacokinetics (PK) study to determine whether DOX levels are altered in the presence of ACEI. In this randomized, cross-over, single-blinded drug-drug interaction study, 19 women with breast cancer prescribed DOX and cyclophosphamide every 14 days received one cycle of DOX chemotherapy with ACEI enalapril 10 mg daily and another cycle of DOX with placebo. Blood samples for DOX and doxorubicinol were drawn at baseline, 0.5, 1.0, 2.0, 4.0, 24.0 and 48.0 hours after infusion with and without ACEI enalapril. Correlative laboratories were also obtained. PK data was analyzed using non compartmental methods and DOX and doxorubicinol area under the curve (AUC) 0 to infinity, Cmax and half-life were estimated. Paired t-tests were used to determine whether DOX and its metabolite were altered with the use of enalapril (P < 0.05). 17 women (median age 45 years) received 60 mg/m2 DOX every two weeks for four cycles. Mean (SD) AUC0- ∞ for DOX and doxorubicinol with enalapril exposure was 1185.56 (44.64) hr*ng/ml and 1040 (80.6) hr*ng/ml, respectively. AUC0- ∞ for DOX and doxobubicinol without enalapril was 1167.73 (45.26) hr*ng/ml and 1056.32 (92.03) hr*ng/ml, respectively. There is no interaction between DOX and enalapril. Enalapril was tolerated (33% grade 1 dizziness). ACEI, enalapril, does not appear to alter the PK of DOX. Ongoing efforts to determine the effectiveness of ACEI as a cardioprotective agent in women receiving DOX chemotherapy should be continued.
7 citations
TL;DR: A trend towards increasing non-relapse mortality (NRM) in frail patients is identified, indicating a need to identify vulnerable populations and define their need for specific interventions.
6 citations
TL;DR: A phase I dose escalation trial of recombinant human IL-15 to enhance adoptive NK cell transfer and observed two patterns of donor cell expansion and autologous count recovery, which suggest that donor NK cells expanded in vivo with IL- 15 are functionally similar to the CD56bright population.
TL;DR: This promising result is the first clear demonstration that ex vivo expanded UCB Treg are potent suppressors of aGVHD in humans and sets the stage for a future pivotal clinical trial that will assess the clinical impact of Treg GVHD prophylaxis on immune recovery and risk of leukemia relapse.
TL;DR: In 4/6 & 4-6/6 transplants, better matching at HLA-C was associated with lower risk of death, treatment failure, and non-relapse death, but there remained no association with risk of relapse.